Umene K   Banno K   Kisu I   Yanokura M   Nogami Y   Tsuji K   Masuda K   Ueki A   Kobayashi Y   Yamagami W   Nomura H   Tominaga E   Susumu N   Aoki D   
Sakai K   Nakamura M   Yamagami W   Chiyoda T   Kobayashi Y   Nishio H   Hayashi S   Nomura H   Kataoka F   Tominaga E   Banno K   Aoki D   
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 29 A580-A580 2019年11月
Nomura H   Aoki D   Susumu N   Mizuno M   Nakai H   Arai M   Nishio S   Tokunaga H   Nakanishi T   Watanabe Y   Yaegashi N   Yokoyama Y   Takehara K   
Nivolumab is a human monoclonal antibody against the immune checkpoint receptor programmed death-1, inhibiting binding to programmed death-ligand 1 or 2 (PD-L1 or PD-L2). This phase 2 study evaluated the efficacy and safety of nivolumab in patient...
Saotome K   Nomura H   Dozen A   Nanki Y   Yoshihama T   Iwasa N   Chiyoda T   Yamagami W   Kataoka F   Hirasawa A   Aoki D   
17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS2018) 2018年9月16日 International Gynecologic Cancer Society
Dozen A   Nomura H   Saotome K   Nanki Y   Yoshihama T   Iwasa N   Chiyoda T   Yamagami W   Kataoka F   Hirasawa A   Aoki D   
17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS2018) 2018年9月15日 International Gynecologic Cancer Society